Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Iparomlimab”

93 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 93 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07263360
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Who this might be right for
BTC
Tianjin Medical University Cancer Institute and Hospital 29
Testing effectiveness (Phase 2)Looking for participantsNCT07165847
What this trial is testing

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Who this might be right for
ImmunotherapyGastric Cancer (GC)Radiotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 40
Post-approval studies (Phase 4)Not Yet RecruitingNCT07004335
What this trial is testing

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Who this might be right for
PD-(L)1CTLA-4Advanced Melanoma+3 more
Hebei Medical University Fourth Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT07150247
What this trial is testing

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Who this might be right for
BRAF V600 Colorectal Cancer
Sun Yat-sen University 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07156682
What this trial is testing

QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer

Who this might be right for
Colon CancerMSS/pMMRQL1706
Qilu Hospital of Shandong University 21
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07379398
What this trial is testing

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Tianjin Medical University Cancer Institute and Hospital 28
Testing effectiveness (Phase 2)Looking for participantsNCT06897046
What this trial is testing

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)II-IIIB
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 90
Testing effectiveness (Phase 2)Looking for participantsNCT07392346
What this trial is testing

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Who this might be right for
Gastric Cancer Adenocarcinoma Metastatic
Dai, Guanghai 68
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07348861
What this trial is testing

A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer

Who this might be right for
Cervical Cancer
Zheng Min 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06936748
What this trial is testing

SFRT+Sequential Hypofractionated/Conventional Fractionated RT+Iparomlimab and Tuvonralimab for Relapsed/Refractory Solid Tumors

Who this might be right for
Cancer
Second Affiliated Hospital of Nanchang University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07396324
What this trial is testing

Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer

Who this might be right for
Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
RenJi Hospital 55
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07372079
What this trial is testing

Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy

Who this might be right for
Breast CancerNeoadjuvant TherapyImmune Checkpoint Inhibitors+1 more
Tianjin Medical University Cancer Institute and Hospital 40
Not applicableNot Yet RecruitingNCT07186868
What this trial is testing

QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer

Who this might be right for
Recurrent Cervical CancerMetastatic Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 25
Large-scale testing (Phase 3)Looking for participantsNCT06749899
What this trial is testing

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Sun Yat-sen University 580
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07009145
What this trial is testing

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

Who this might be right for
Unresectable Colorectal CancerMetastatic Colorectal Cancer (CRC)MSI-H/dMMR Colorectal Cancer
Qianfoshan Hospital 22
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07131345
What this trial is testing

Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma

Who this might be right for
Malignant MesotheliomaMesothelioma
National Cancer Center, China 55
Testing effectiveness (Phase 2)Looking for participantsNCT07389629
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

Who this might be right for
Iparomlimab and TuvonralimabClear Cell Renal Cell CarcinomaNeoadjuvant Therapy
Sun Yat-sen University 25
Not applicableNot Yet RecruitingNCT07115550
What this trial is testing

A Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
Huai'an First People's Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT07038629
What this trial is testing

Chemoradiation Plus Iparomlimab Consolidation in Older With ESCC

Who this might be right for
Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital 52
Testing effectiveness (Phase 2)Looking for participantsNCT07055399
What this trial is testing

Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC)

Who this might be right for
Locally Advanced Cervical Cancer
Fujian Cancer Hospital 43
Load More Results